Search

Displaying results 3481 - 3490 of 7018 in total
  1. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory

    Synonyms: human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins under control of a
  2. Drug

    Iodipamide

    go.drugbank.com/drugs/DB04711
    ApprovedWithdrawn

    Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. … Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.

  4. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    It is produced by Streptomyces capreolus.

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  5. Drug

    ADL 10-0101

    go.drugbank.com/drugs/DB05443
    Experimental

    Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects. … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate.

  6. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

  7. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug. … Like other amphetamines, this amphetamine analog was used as an appetite suppressant in the 1950s.

  8. Drug

    AEM-28-14

    go.drugbank.com/drugs/DB17643
    Experimental

    AEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability. … [L45909] It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.[L45914]

  9. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. … In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

  10. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. … Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH.